Corporate Tech Investors

BioMotiv

BioMotiv is a corporate venture capital group that partners with startup ventures that can advance its organizational interests.

Venture Investor Overview

Contact Information

Background Information

Overview

BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center's Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

1/6/2021

Transaction History

Our records indicate that BioMotiv invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

Baiju Shah

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

BioMotiv has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

bioMerieux | Biosynex

Share this article

About Our Corporate Tech Investor Database

The strategic investor data above is provided by VentureDeal.com, a leading provider of corporate tech investing transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary